Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Surgical Oncology

Managing the Gastrinoma: Surgical and Medical Options

At a Glance

Zollinger-Ellison syndrome treatment has two goals: PPIs control excess stomach acid, while surgery or tumor-directed medicines control the gastrinoma. Localized sporadic tumors may be curable with surgery; MEN1, tumor grade, receptor status, spread, and surgical risk guide other choices.

While proton pump inhibitors (PPIs) are essential for managing excess acid, they do not treat the underlying gastrinoma (the tumor itself). Treatment of the tumor focuses on controlling its growth and, when possible, achieving a complete cure [1][2]. The approach depends heavily on whether your ZES is sporadic or related to the MEN1 genetic syndrome, as well as the tumor’s stage, grade, and your overall health.

Surgery for Sporadic Gastrinoma

In sporadic ZES, the tumor is often a single, solitary lesion [3]. For localized sporadic disease, surgery is generally considered at an experienced center because it offers the only chance for a permanent cure [1][4].

  • Surgical Evaluation: Specialists may recommend surgery if the disease appears localized. Even if scans are negative, a high-volume center might consider exploratory surgery because gastrinomas are frequently very small [1][5]. However, this is not an automatic decision; it depends on biochemical certainty, tumor grade, and comorbidity.
  • The Surgical Approach: The operation typically involves exploring the gastrinoma triangle, removing the primary tumor via a duodenotomy (carefully opening the small intestine), and removing regional lymph nodes [4][5].
  • Outcomes: When a sporadic gastrinoma is completely removed, some patients are cured and can eventually stop their acid medications under careful supervision [5][6]. However, recurrence is still possible, and long-term biochemical follow-up is necessary.

The MEN1 Surgical Controversy

Surgery for patients with MEN1-associated ZES is much more complex and remains a subject of debate among experts [7][4]. MEN1 gastrinomas are almost always multifocal, meaning there are many tiny tumors scattered throughout the duodenum [8][9].

  • The Challenge of Cure: Removing just the “visible” tumors rarely cures the condition; remaining microscopic tumors continue to produce gastrin [8][9].
  • The 2 cm Threshold: To balance the risks of major surgery against the risk of cancer spread, some guidelines use a tumor size of 2 centimeters as a rough threshold for considering surgery [10][11]. However, this is not a universal rule. Decisions are also based on the tumor’s growth rate, grade (Ki-67 index), nodal disease, hormone control, and your age [10][4].
  • Aggressive vs. Conservative: Some centers favor aggressive surgery to prevent spread, while others recommend a “watch and wait” approach since the acid can be controlled medically [7][4].

Understanding Surgical Risks

Surgery in the pancreas and duodenum is major. Procedures range from localized enucleation to a Whipple procedure (pancreaticoduodenectomy). Risks include pancreatic leaks, delayed gastric emptying, digestive or bowel changes, pancreatic enzyme insufficiency (requiring you to take enzymes with meals), and the development of diabetes [10]. You and your surgeon must weigh these risks against the benefits.

Managing Advanced Disease

If a gastrinoma is metastatic (e.g., has spread to the liver) or unresectable, the disease is often still manageable for long periods. The focus shifts to controlling tumor growth, guided by the tumor’s differentiation and receptor status [12][13].

  • Somatostatin Analogues (SSAs): Medications like octreotide or lanreotide are used as anti-proliferative therapy for well-differentiated tumors [12][14]. These injections slow down tumor cell growth [15]. SSAs are used for tumor control; they do not replace PPIs for controlling the severe acid production of ZES [12][2].
  • PRRT (Peptide Receptor Radionuclide Therapy): For well-differentiated, somatostatin-receptor positive tumors that progress on SSAs, PRRT (such as Lutathera) may be an option [16]. This treatment delivers targeted radiation to the tumor cells [16][17]. Eligibility depends on kidney and bone marrow function.
  • Other Options: Liver-directed therapies (like embolization), systemic chemotherapy, or cytoreductive surgery (to “debulk” the tumor and reduce hormone burden) may also be considered in specific circumstances [13][18].

Choosing the right path requires a multidisciplinary team—including a NET surgeon, an endocrinologist, and a medical oncologist [7].

Common questions in this guide

Can surgery cure a gastrinoma in Zollinger-Ellison syndrome?
For a localized sporadic gastrinoma, complete surgical removal may provide a permanent cure and may allow some people to stop acid-reducing medicine under close supervision. The tumor can return, so long-term blood-test follow-up is still needed.
Why is surgery different when Zollinger-Ellison syndrome is linked to MEN1?
MEN1-associated gastrinomas are usually multiple tiny tumors, so removing only the tumors seen during surgery may not eliminate the source of excess gastrin. Doctors weigh tumor size, growth, grade, lymph-node involvement, acid control, age, and the risks of major surgery; some patients are monitored instead.
Can I stop my PPI if I receive octreotide or lanreotide?
Usually not automatically. Octreotide and lanreotide are used mainly to slow tumor growth, while PPIs control the severe stomach-acid production caused by Zollinger-Ellison syndrome. Only change or stop a PPI with the clinician managing your acid levels.
What treatments are available if a gastrinoma has spread to the liver?
Advanced or inoperable gastrinoma can often be managed for long periods, with treatment chosen according to how the tumor is differentiated and which receptors it carries. Options may include somatostatin medicines, PRRT for suitable receptor-positive tumors, liver-directed treatment, chemotherapy, or surgery to reduce tumor size and hormone production. PRRT also requires appropriate kidney and bone marrow function.
What are the risks of surgery for a gastrinoma?
Surgery involving the pancreas or duodenum is major and can cause a pancreatic leak, delayed stomach emptying, digestive or bowel changes, reduced pancreatic enzymes, or diabetes. The risk depends on the operation, from a localized procedure to a Whipple operation, and on your overall health.
Could surgery be considered if scans do not show my gastrinoma?
Yes, an experienced center may consider exploratory surgery because gastrinomas can be very small, but negative imaging alone does not make surgery necessary. The decision depends on how certain the laboratory diagnosis is, tumor grade, other health conditions, and whether the disease appears localized.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my gastrinoma considered sporadic or MEN1-associated, and how does that change the goal of surgery?
  2. 2.If my imaging is negative but my labs confirm ZES, what factors make exploratory surgery a good or bad option for me?
  3. 3.What are the specific risks for me if we choose a more extensive surgery (like a Whipple procedure) versus a more localized duodenal surgery?
  4. 4.For my MEN1, how are we weighing tumor size, growth rate, and grade to decide on surgery?
  5. 5.If we use a somatostatin analogue (SSA) for tumor control, will I still need to take my high-dose PPI for acid management?
  6. 6.What is the plan if the tumor has already spread to my lymph nodes or liver—are liver-directed therapies or PRRT options for my specific tumor grade?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.

    Chatzipanagiotou O, Schizas D, Vailas M, et al.

    Journal of neuroendocrinology 2023; (35(4)):e13267 doi:10.1111/jne.13267.

    PMID: 37042078
  2. 2

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  3. 3

    [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].

    Guo Y, Chen LH, Liu M, et al.

    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021; (24(10)):875-882 doi:10.3760/cma.j.cn.441530-20210719-00291.

    PMID: 34674462
  4. 4

    Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies.

    Shao QQ, Zhao BB, Dong LB, et al.

    World journal of gastroenterology 2019; (25(32)):4673-4681 doi:10.3748/wjg.v25.i32.4673.

    PMID: 31528093
  5. 5

    Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure?

    Robin L, Sauvanet A, Walter T, et al.

    Surgery 2023; (173(5)):1144-1152 doi:10.1016/j.surg.2022.12.030.

    PMID: 36781315
  6. 6

    [Management of gastrinoma].

    Hain E, Coriat R, Dousset B, Gaujoux S

    Presse medicale (Paris, France : 1983) 2016; (45(11)):986-991 doi:10.1016/j.lpm.2016.04.012.

    PMID: 27262229
  7. 7

    How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

    Imamura M, Komoto I, Taki Y

    Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.

    PMID: 36473964
  8. 8

    Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

    Gaujoux S, Pattou F, Cadiot G, et al.

    World journal of surgery 2026; (50(5)):1300-1311 doi:10.1002/wjs.70303.

    PMID: 41862416
  9. 9

    Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1.

    Albers MB, Manoharan J, Bartsch DK

    Best practice & research. Clinical endocrinology & metabolism 2019; (33(5)):101318 doi:10.1016/j.beem.2019.101318.

    PMID: 31521501
  10. 10

    Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne).

    Vinault S, Mariet AS, Le Bras M, et al.

    Annals of surgery 2020; (272(6)):1094-1101 doi:10.1097/SLA.0000000000003162.

    PMID: 30585820
  11. 11

    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

    van Beek DJ, Nell S, Pieterman CRC, et al.

    Journal of surgical oncology 2019; (120(6)):966-975 doi:10.1002/jso.25667.

    PMID: 31401809
  12. 12

    The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

    Guarnotta V, Martini C, Davì MV, et al.

    Endocrine 2018; (60(1)):15-27 doi:10.1007/s12020-017-1420-4.

    PMID: 29019150
  13. 13

    Surgical Management of Neuroendocrine Tumor Liver Metastases.

    Tran CG, Sherman SK, Chandrasekharan C, Howe JR

    Surgical oncology clinics of North America 2021; (30(1)):39-55 doi:10.1016/j.soc.2020.08.001.

    PMID: 33220808
  14. 14

    European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

    Hofland J, Falconi M, Christ E, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13318 doi:10.1111/jne.13318.

    PMID: 37578384
  15. 15

    Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study.

    Massironi S, Cavalcoli F, Elvevi A, et al.

    Endocrine 2022; (75(3)):942-948 doi:10.1007/s12020-021-02915-7.

    PMID: 34716542
  16. 16

    Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

    Zandee WT, Brabander T, Blažević A, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(4)):1336-1344 doi:10.1210/jc.2018-01991.

    PMID: 30566620
  17. 17

    Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications.

    Di Franco M, Durmo R, Di Paolo ML, et al.

    Frontiers in oncology 2025; (15()):1590478 doi:10.3389/fonc.2025.1590478.

    PMID: 40458720
  18. 18

    Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.

    Siebenhüner AR, Langheinrich M, Friemel J, et al.

    Cancers 2022; (14(6)) doi:10.3390/cancers14061478.

    PMID: 35326628

This page explains surgical and medical treatment choices for gastrinoma in Zollinger-Ellison syndrome for informational purposes only and does not constitute medical advice. Discuss your tumor results, treatment options, and surgical risks with your surgeon, endocrinologist, and oncologist.

Get notified when new evidence is published on Zollinger-Ellison syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.